Reporting partial recognition of Sancuso split payment revenue for fiscal 2026 related to the agreement with MAAB. Revised the 2026 product sales revenue estimate to 350 million yen and cost of goods sold estimate to 190 million yen. The overall expected amount of license revenue and timing of further disclosure remain withheld.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4597","jir_company_name":"Solasia Pharma K.K.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4597-20261019-01.pdf","jir_short_summary":"Reporting partial recognition of Sancuso split payment revenue for fiscal 2026 related to the agreement with MAAB. Revised the 2026 product sales revenue estimate to 350 million yen and cost of goods sold estimate to 190 million yen. The overall expected amount of license revenue and timing of further disclosure remain withheld.","jir_summary":"### Key News Points\nPartial recognition of the Sancuso\u00ae split payment revenue is planned in the current fiscal settlement in relation to the agreement with MAAB. The 2026 product sales revenue estimate has been revised to 350 million yen and the cost of goods sold estimate to 190 million yen. The overall license revenue outlook and timing of any further disclosures will continue to be withheld.\n\n### Future Impact and Considerations\nDepressed shipment levels are affecting the 2026 revenue outlook, and external factors such as foreign exchange may also impact results. Only certain previously disclosed items have been revised; publication of the overall forecast remains withheld.","jir_financial_highlights":"Recognition of Sancuso split payment revenue (partial): Unknown (Unknown)\n2026 product sales revenue estimate: 350 million yen (Revised (impact of depressed shipment levels of Epithil to China))\n2026 cost of goods sold estimate: 190 million yen (Revised (same depressed shipment impact))","jir_category":"","jir_hashtags":"#SolasiaPharma, #NotShareBuyback_IRSpecialistContent, #Earnings","jir_key_figures":"Partial recognition of Sancuso split payment revenue (Unknown)\n2026 product sales revenue estimate = 350 million yen\n2026 cost of goods sold estimate = 190 million yen","jir_meta_title":"Solasia Pharma K.K. Announces Recognition of Sancuso Split Payment and Revision of 2026 Estimates | 2026","jir_meta_description":"Solasia Pharma K.K. reports partial recognition of Sancuso split payment revenue and revises its 2026 product sales revenue estimate to 350 million yen and cost of goods sold estimate to 190 million yen. The announcement also outlines its disclosure policy going forward.","jir_og_title":"Solasia Pharma K.K. \u2014 Recognition of Sancuso Split Payment and Revised Estimates","jir_og_description":"Announcing partial recognition of Sancuso split payment revenue and revisions to 2026 revenue estimates. The company also clarifies its policy on future disclosures.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59381,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-132608","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n